Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of fostamatinib in methotrexate-refractory rheumatoid arthritis
2008-000742-30Phase 2Terminated
- Sponsor
- Rigel Pharmaceuticals, Inc.
- Start
- Apr 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of fostamatinib in rheumatoid arthritis (RA) (3 arms), sponsored by Rigel Pharmaceuticals, Inc. Primary endpoint: ACR20 response rate at Month 6. Started Apr 2008; status: terminated.
02
Drugs
fostamatinib
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on 2008-000742-30.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-000742-30.